Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phenserine vs Donepezil in Early or Mild Alzheimer's Disease
NCT06774261Phase 1Completed
- Sponsor
- Stavanger University Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of phenserine in Alzheimer's disease (AD) (2 arms), sponsored by Stavanger University Hospital. Primary endpoints: Concentration of Biomarkers Associated with Preprogrammed Cell Death at 8 weeks, Concentration of Synaptic Integrity Biomarkers at 8 weeks and 3 more. Started Feb 2025; status: completed.
02
Drugs
phenserine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06774261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06774261.